<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of infections following hematopoietic cell transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of infections following hematopoietic cell transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of infections following hematopoietic cell transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Wingard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3926169"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hematopoietic cell transplant (HCT) recipients, especially those who have received allogeneic transplants, are at substantial risk for a variety of infections depending upon the degree of immunodeficiency, exposure to pathogens, and the time elapsed since transplantation. HCT patients are at risk for infectious diseases resulting from bacteria, fungi, viruses, and/or parasites, all of which are associated with higher morbidity and mortality than in immunocompetent individuals.</p><p>The term "hematopoietic cell transplantation" will be used throughout this topic as a general term to cover transplantation of hematopoietic cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Possible sources for these cells include the patient's own cells (autologous); an identical twin (syngeneic, human leukocyte antigen [HLA] identical); a sibling, a related, or an unrelated donor (allogeneic; HLA identical, haploidentical, or mismatched); or umbilical cord blood (UCB; HLA identical, haploidentical, or mismatched). (See  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p>An overview of infections following HCT will be presented here and will be organized by risk period and clinical syndrome; the syndromes discussed are often infectious in nature but may also have noninfectious etiologies. The evaluation for infection and prevention of infection in HCT recipients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H1909224400"><span class="h1">RISK OF INFECTION</span><span class="headingEndMark"> — </span>It is important to identify the population at high risk for infections and also the magnitude of and period of highest risk in order to predict which patients are most likely to benefit from targeted prophylaxis, diagnostic procedures, and/or pre-emptive therapy. The risk of infection results from the interaction of at least three factors  (<a class="graphic graphic_figure graphicRef50448" href="/d/graphic/50448.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The intensity of exposure to and the relative virulence of the offending microorganisms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient's specific immune effectors and the patient's net state of immunosuppression (type, degree, pace, and duration)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of tissue and/or organ damage (eg, mucositis, renal failure, lung damage) and/or the use of central venous catheters</p><p></p><p>Depending on these interactions, patients can be stratified as being at high or low risk for infection  (<a class="graphic graphic_table graphicRef70011" href="/d/graphic/70011.html" rel="external">table 1</a>). This risk decreases with hematologic reconstitution, specifically with reconstitution of innate and adaptive cellular immune effectors. Immune reconstitution is typically faster in autologous hematopoietic cell transplantation (HCT) recipients than in allogeneic HCT recipients. In the allogeneic HCT recipients, immune reconstitution can be delayed by various factors, which are discussed below. Immune reconstitution following HCT is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16355.html" rel="external">"Strategies for immune reconstitution following allogeneic hematopoietic cell transplantation", section on 'Overview of immune reconstitution'</a>.)</p><p>Among allogeneic HCT recipients, the most important risk factors for infection include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High HCT comorbidity index (see  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation", section on 'Risk assessment scoring systems'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disease and prior therapy-related factors:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The underlying disease, particularly in the setting of extensive prior therapy (eg, multiple myeloma after prolonged therapy with glucocorticoids [<a href="#rid2">2</a>]; chronic lymphocytic leukemia after therapy with a purine analog [<a href="#rid3">3</a>]) (see  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prior HCT</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prior infections of the donor and/or recipient (see  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Presence of pretransplant-specific immunity to cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), and/or Epstein-Barr virus (EBV)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Iron overload</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant-related factors  (<a class="graphic graphic_table graphicRef98314" href="/d/graphic/98314.html" rel="external">table 2</a>)<strong>:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myeloablative conditioning regimens (see  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation", section on 'Myeloablative regimens'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Degree of donor/recipient human leukocyte antigen (HLA) mismatch, with higher infectious risk with use of mismatched or partially matched (haploidentical) allografts (see  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Graft source – Peripheral blood stem cells are associated with faster neutrophil engraftment than marrow or cord blood but more chronic graft-versus-host disease (GVHD); umbilical cord blood is associated with slower neutrophil engraftment and slower B and T cell immune reconstitution but less GVHD compared with marrow or peripheral blood (see  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T cell depletion (or CD34+ cell selection, which effectively removes T cells) is associated with greater risk for graft rejection, slower B and T cell immune reconstitution, greater risk for neutropenic infections, lower risk for GVHD and infections associated with GVHD, and greater and longer risk for herpesvirus and invasive fungal infections (see  <a class="medical medical_review" href="/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease", section on 'T cell depletion (TCD)'</a> and  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunosuppressive regimen – More profound deficiency of T cell immunity with antithymocyte globulin; more mucosal injury and longer time to neutrophil engraftment with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunogenetics – Examples of polymorphisms that confer increased or decreased risk of infection include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polymorphisms in recipient mannose-binding lectin mutations have been associated with increased infections after engraftment following myeloablative sibling allogeneic HCT [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Various gene polymorphisms (in HCT donors, HCT recipients, or patients with hematologic malignancies) have been associated with an increased risk of invasive aspergillosis in HCT recipients and/or patients with hematologic malignancies. Examples include polymorphisms in genes involved in the innate immune response, such as the toll-like receptor 4 gene [<a href="#rid5">5</a>]; the soluble pattern recognition receptor, long pentraxin 3 (PTX3) [<a href="#rid6">6</a>]; dectin-1 [<a href="#rid7">7,8</a>]; and others [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protection from CMV reactivation was shown to be related to different genotypes of donor-activated killer-immunoglobulin receptors [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged and severe neutropenia – The Multinational Association for Supportive Care in Cancer risk index is a validated tool for measuring the risk for neutropenic fever-related medical complications (<a class="calc calc_professional" href="/d/html/16931.html" rel="external">calculator 1</a>) [<a href="#rid11">11-14</a>]; this risk index and other methods for assessing risk of complications in neutropenic patients are discussed in detail separately (see  <a class="medical medical_review" href="/d/html/16888.html" rel="external">"Risk assessment of adults with chemotherapy-induced neutropenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute and extensive chronic GVHD and its therapy (particularly with high-dose glucocorticoids and novel immunosuppressants) leading to delayed immune reconstitution (see  <a class="medical medical_review" href="/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)"</a> and  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease", section on 'Introduction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection with immunomodulating viruses, particularly CMV [<a href="#rid15">15</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Graft failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory complications, such as airflow decline [<a href="#rid16">16</a>]</p><p></p><p>Many of the risk factors for infection are interrelated. As an example, duration of neutropenia is related to patient and transplant variables including underlying disease, extensive prior therapy, stem cell source (cord) and cell dose (low), conditioning regimen (myeloablative), graft failure or rejection, and others. Similarly, many risk factors increase the risk for GVHD, including stem cell source (peripheral stem cell more than bone marrow) and HLA relatedness (mismatched or unrelated donor more than matched related).</p><p>A careful pretransplant screening of donor and recipient to evaluate the risk of post-transplant infection is one of the most important steps in the management of HCT recipients. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H503783707"><span class="h1">TIMELINE FOR INFECTIONS</span><span class="headingEndMark"> — </span>The types of infections to which hematopoietic cell transplantation (HCT) recipients are most vulnerable can be roughly divided based upon the time elapsed since transplantation [<a href="#rid1">1,17</a>]. The three periods are:</p><p class="bulletIndent1"><span class="glyph">●</span>Pre-engraftment – From transplantation to neutrophil recovery, approximately day 20 to 30</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early postengraftment – From engraftment to day 100</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late postengraftment – After day 100</p><p></p><p>It is useful to think of the most likely infectious disease manifestations during each period among allogeneic and autologous HCT recipients and also to think of the clinical syndromes that occur during each period  (<a class="graphic graphic_table graphicRef50318" href="/d/graphic/50318.html" rel="external">table 3</a>). Both perspectives offer complementary information. Knowledge of likely pathogens during each period facilitates decisions about the need for and potential benefit of prophylaxis and to allow the clinician to construct a differential diagnosis for clinical syndromes that occur. For many clinical syndromes that occur after HCT, there are possible infectious and noninfectious etiologies.</p><p>This division into time periods is artificial, but it is helpful in the management of HCT recipients. The timing and length of interval of each of these phases may vary according to the source of stem cells, degree of human leukocyte antigen (HLA) and minor histocompatability antigen match, the type and intensity of conditioning regimen used, and any manipulation of the graft to remove T cells or other cell populations, the type of post-transplant immunosuppressive therapy (especially glucocorticoids), and the presence of graft-versus-host disease (GVHD). In general, allogeneic HCT recipients are at risk for infection during all three periods  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 2</a>), whereas autologous HCT recipients are typically only vulnerable to infection during the pre- and immediate postengraftment periods  (<a class="graphic graphic_figure graphicRef64491" href="/d/graphic/64491.html" rel="external">figure 3</a>). During each of these time periods, patients can develop bacterial, fungal, viral, and/or parasitic infections, although certain pathogens tend to cause disease during some of these periods more frequently than others  (<a class="graphic graphic_table graphicRef50318" href="/d/graphic/50318.html" rel="external">table 3</a>).</p><p>In HCT recipients, the general risk of infectious complications is not limited to the period of granulocytopenia but persists for 6 to 12 months after autologous HCT and 12 to 24 months after allogeneic HCT, until B and T cell immune recovery occurs. The period of increased risk for infection includes the period during which the patient is profoundly neutropenic (absolute neutrophil count ≤100 cells/microL) and/or lymphopenic (absolute lymphocyte count ≤300 cells/microL) [<a href="#rid1">1</a>]. Receipt of T cell suppressive therapies (high-dose glucocorticoids, anti–T cell antibodies, purine analogs, others), the occurrence of GVHD, and/or receipt of a T cell–depleted hematopoietic cell graft may delay T cell recovery, and use of agents such as <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> may delay B cell recovery [<a href="#rid18">18</a>]. The risk for infection usually decreases six months after the last dose of T cell suppressive therapies or when the absolute lymphocyte count is ≥500 cells/microL (or the absolute CD4 count is ≥200 cells/microL), whichever is longer. (See  <a class="medical medical_review" href="/d/html/16355.html" rel="external">"Strategies for immune reconstitution following allogeneic hematopoietic cell transplantation", section on 'Overview of immune reconstitution'</a>.)</p><p class="headingAnchor" id="H3926176"><span class="h1">PRE-ENGRAFTMENT PERIOD</span><span class="headingEndMark"> — </span>The major risk factors for infection during the pre-engraftment period after hematopoietic cell transplantation (HCT) are mucocutaneous damage, which disrupts the natural barriers of the skin and mucous membranes, and neutropenia, with resulting loss of phagocytic abilities  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef64491" href="/d/graphic/64491.html" rel="external">figure 3</a>) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H12424739"><span class="h2">Neutropenic fever</span><span class="headingEndMark"> — </span>Neutropenic fever occurs in most HCT patients during the pre-engraftment period. An infectious source is identified in only 20 to 30 percent of febrile neutropenic episodes [<a href="#rid19">19,20</a>]. Often, fever is the only evidence of infection. Bacteremia is documented by blood cultures in 10 to 25 percent of patients with neutropenic fever [<a href="#rid19">19</a>]. Aerobic gram-positive and gram-negative bacteria account for most neutropenic fevers during this period.</p><p>In addition to fever, infectious complications present as pneumonia and lower gastrointestinal tract infection (neutropenic enterocolitis or <em>Clostridioides</em> <em>difficile</em> colitis). Less frequent manifestations include septic shock, ecthyma gangrenosum, and perirectal cellulitis.</p><p>Antibacterial prophylaxis reduces the risk of bacterial infections, mainly bacteremias, during neutropenia. The evaluation and management approaches are similar to those used for neutropenic fever in nontransplant high-risk patients. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a> and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a>.)</p><p>The greatest risk for infection during neutropenia is in HCT patients who receive myeloablative conditioning, which produces more mucosal injury and longer durations of neutropenia compared with nonmyeloablative conditioning. Antibiotic prophylaxis is generally recommended in such high-risk patients (see  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'Antibacterial prophylaxis'</a>).</p><p>Persistent fever has a wide differential diagnosis, including antibiotic-resistant bacteria, fungi (especially <em>Candida</em>, less commonly <em>Aspergillus</em>), occult infection, inflammatory response to tissue damage, and drug fever (see  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>). Antifungal prophylaxis is recommended in such high-risk patients [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a>.)</p><p class="headingAnchor" id="H12424825"><span class="h2">Mucositis</span><span class="headingEndMark"> — </span>Mucositis of the oral cavity, oropharynx, and esophagus is most common in patients receiving myeloablative conditioning regimens and is principally due to mucosal toxicity. However, herpes simplex virus (HSV) reactivation occurs in two-thirds of HSV-seropositive patients not receiving specific antiviral prophylaxis. HSV can exacerbate mucositis [<a href="#rid23">23,24</a>] and occasionally cause esophagitis. Antiviral prophylaxis is highly effective in preventing HSV reactivation. Rarely, deep punched-out localized oral ulcers can be caused by the agents of mucormycosis, <em>Fusarium</em> spp, or other pathogenic molds. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p class="headingAnchor" id="H12424899"><span class="h2">Diarrhea</span><span class="headingEndMark"> — </span>Diarrhea is common and can have both infectious and noninfectious etiologies. Mucosal injury due to the conditioning regimen is a frequent cause of diarrhea during the first week after HCT and is most common after myeloablative conditioning regimens. Multiple medications, particularly oral magnesium supplements given to counter the hypomagnesemia often seen with calcineurin inhibitors, are frequent causes of diarrhea.</p><p>One of the most common causes of infectious diarrhea in patients undergoing HCT is <em>C. difficile</em>–associated diarrhea (CDAD), with incidences as high as 10 to 30 percent in some studies [<a href="#rid25">25-28</a>]. Of particular concern is the increasing worldwide prevalence of CDAD caused by a hypervirulent strain of <em>C. difficile</em>. Clinicians should remain vigilant about the possibility of CDAD in any patient with significant diarrhea and/or abdominal pain. (See  <a class="medical medical_review" href="/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a>.)</p><p>Another frequent cause of diarrhea is neutropenic enterocolitis (or typhlitis). Fever, diarrhea, abdominal pain or distention, and tenderness are often present. This is covered in detail separately. (See  <a class="medical medical_review" href="/d/html/2690.html" rel="external">"Neutropenic enterocolitis (typhlitis)"</a>.)</p><p>Multiple other enteric pathogens can also cause diarrhea and should be excluded. (See <a class="local">'Diarrhea'</a> below and  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H12424964"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>Pneumonia can be caused by both infectious and noninfectious etiologies. The differential diagnosis is highly influenced by the type of infiltrate. Pulmonary infiltrates can be divided into nodular (or localized) or diffuse infiltrates.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular lesions</strong> – Most nodular lesions are caused by infectious etiologies during the pre-engraftment period [<a href="#rid29">29</a>]. Both bacterial (gram positive and gram negative) and, less commonly, mold pathogens predominate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse infiltrates</strong> – Diffuse infiltrates during this period are more common due to noninfectious causes such as pulmonary edema or lung damage resulting from the conditioning regimen  (<a class="graphic graphic_table graphicRef83194" href="/d/graphic/83194.html" rel="external">table 4</a>). However, respiratory viruses may be causes of both upper and lower respiratory tract infections, with the latter manifesting commonly as diffuse or patchy infiltrates.</p><p></p><p>It is important to note that pulmonary infiltrates (typically a diffuse pattern) that coincide with engraftment are often not infectious but, rather, are due to hemorrhagic alveolitis or to a cytokine-driven inflammatory process known as engraftment syndrome. The engraftment syndrome has been reported in 7 to 10 percent of autologous HCT recipients but less commonly following allogeneic HCT. (See  <a class="medical medical_review" href="/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation", section on 'Engraftment syndrome and PERDS'</a> and  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Engraftment syndrome'</a>.)</p><p class="headingAnchor" id="H12424992"><span class="h2">Vascular catheter-associated cellulitis</span><span class="headingEndMark"> — </span>Erythema, pain, swelling, and/or tenderness on palpation at the insertion site of the catheter or along the catheter subcutaneous track are common manifestations of vascular catheter-associated cellulitis. Cultures of secretions at the exit site or bloodstream may be helpful and should be done, but cultures are often negative; accordingly, presumptive therapy is justified and agents chosen to cover the most likely pathogens. Blood cultures should also be performed since bacteremia may occur. At least half of the pathogens are staphylococci (especially <em>Staphylococcus epidermidis</em>). Evaluation and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>.)</p><p class="headingAnchor" id="H1909223439"><span class="h2">Bloodstream infection</span><span class="headingEndMark"> — </span>Bloodstream infections are common in HCT recipients, often related to the central venous line (CVL) or mucosal injury. Gram-positive bacteria (<em>S. epidermidis</em>, <em>Staphylococcus aureus</em>) are most common, but gram-negative bacteria and <em>Candida</em> spp bloodstream infections also occur. Possible sources other than the CVL include the gastrointestinal tract and, for bacterial infections, the lungs. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Bacterial pathogens'</a> and  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Fungal pathogens'</a> and  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H503784216"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Infectious causes of hepatocellular injury are uncommon during this period. Hepatic sinusoidal obstruction syndrome (formerly known as venoocclusive disease) generally first manifests during the pre-engraftment period and its onset is rare after day 30. Occasionally, acute cholecystitis may occur and should be considered in patients with a syndrome that involves cholestasis. (See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a> and  <a class="medical medical_review" href="/d/html/129810.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children"</a>.)</p><p class="headingAnchor" id="H258911"><span class="h2">Hemorrhagic cystitis</span><span class="headingEndMark"> — </span>Pre-engraftment hemorrhagic cystitis is typically caused by toxicity to the bladder mucosa from the conditioning regimen (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, total body irradiation) [<a href="#rid30">30,31</a>]. In contrast, postengraftment hemorrhagic cystitis is often caused by a virus, such as BK polyomavirus or adenovirus. (See <a class="local">'Hemorrhagic cystitis'</a> below.)</p><p class="headingAnchor" id="H3926183"><span class="h1">EARLY POSTENGRAFTMENT PERIOD</span><span class="headingEndMark"> — </span>The major risk factors for infection during the early postengraftment period (days 30 to 100 after hematopoietic cell transplantation [HCT]) are acute graft-versus-host disease (GVHD) and its therapy as well as residual mucositis and cutaneous damage (similar to pre-engraftment) and recurrent or ongoing neutropenia  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef64491" href="/d/graphic/64491.html" rel="external">figure 3</a>) [<a href="#rid32">32</a>]<em>.</em> Various pathogens cause infection during this period.</p><p class="headingAnchor" id="H12425011"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>Pneumonia is a common complication during the early postengraftment period. The radiologic pattern (nodular versus diffuse), as in the pre-engraftment period, drives the differential diagnostic considerations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular lesions</strong> – Nodular pneumonias are most likely infectious, with both bacterial (gram positive and gram negative) and molds being most likely [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">In contrast with the pre-engraftment period, invasive aspergillosis (and less commonly other molds) is a more frequent cause of nodular infiltrates, causing 40 to 50 percent of nodular pneumonias and aggressive therapy, and diagnostic assessment is recommended [<a href="#rid29">29</a>]. Invasive aspergillosis can occur among both allogeneic and autologous HCT recipients, although the incidence is higher among the former group (5 to 30 percent versus 1 to 5 percent) [<a href="#rid33">33-36</a>]. (See  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p></p><p class="bulletIndent1">Although various risk factors for postengraftment invasive aspergillosis have been identified, GVHD (acute and chronic) and cytomegalovirus (CMV) disease have been the most consistently identified [<a href="#rid37">37</a>]. <em>Aspergillus</em> accounts for approximately 90 percent of pulmonary fungal infections. However, there has been increasing recognition of the less common but potentially fatal opportunistic mycoses in HCT recipients, including those caused by the agents of mucormycosis (accounting for 5 to 10 percent of pulmonary fungal infections) and, less frequently, <em>Fusarium</em> spp, <em>Scedosporium apiospermum </em>complex, and others [<a href="#rid33">33,38</a>]. The clinical features of these infections often mimic aspergillosis, although fusariosis has some unique manifestations, which include skin lesions and bloodstream infections [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/16218.html" rel="external">"Clinical manifestations and diagnosis of Fusarium infection"</a> and  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a> and  <a class="medical medical_review" href="/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse infiltrates</strong> – For diffuse infiltrates, infectious causes are much more frequent during the early postengraftment period than during the pre-engraftment period  (<a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 5</a>). CMV, respiratory viruses, and <em>Pneumocystis</em> pneumonia (PCP) are more likely causes, whereas they are infrequent prior to engraftment. Idiopathic pneumonitis due to toxicity from the conditioning regimen is also a common cause of diffuse infiltrates in this period, especially in allogeneic HCT recipients who receive ablative conditioning regimens. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Idiopathic pneumonia syndrome'</a>.)</p><p></p><p>Specific causes of pneumonia that are important to consider include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Pneumocystis</em></strong> – PCP is uncommon (&lt;1 percent) in HCT recipients receiving prophylaxis with <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) [<a href="#rid40">40-43</a>]. The diagnosis of PCP should be considered in patients with high fever, dry cough, hypoxemia, and interstitial pneumonitis who are at risk but are not being given prophylaxis, who are being given suboptimal agents (aerosolized <a class="drug drug_general" data-topicid="9752" href="/d/drug information/9752.html" rel="external">pentamidine</a> or <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> given on alternate days), or who are nonadherent to the prophylactic regimen. A significant risk for developing PCP has been reported when dapsone was given three times per week (7.2 versus 0.37 percent for TMP-SMX) [<a href="#rid42">42</a>] but not when daily doses of dapsone were given to patients. The efficacy of daily dapsone in preventing PCP appears to be similar with that observed in patients able to remain on TMP-SMX prophylaxis [<a href="#rid44">44</a>]. Prophylaxis with aerosolized pentamidine is less effective than with TMP-SMX or dapsone (when given daily) [<a href="#rid45">45</a>]. Risk factors for PCP include prolonged administration of immunosuppressive therapies (high-dose glucocorticoids), chronic GVHD, therapy with purine analogs or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, a CD4+ T cell count &lt;200 cells/microL, and relapse of hematologic malignancy [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients", section on 'Pneumocystis prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory viruses</strong> – Respiratory viruses may cause both upper and lower respiratory tract infections, with the latter typically manifesting radiologically as diffuse or patchy infiltrates. It is important to note that prolonged asymptomatic viral shedding may also occur in the absence of clinical illness and may be detected along with copathogens such as CMV, <em>Aspergillus</em> spp, or <em>Pneumocystis jirovecii</em>. These copathogens may cause or contribute to lower respiratory tract disease and require therapy. [<a href="#rid46">46-49</a>]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; the virus that causes coronavirus disease 2019 [COVID-19]) is among the group of respiratory viral pathogens that can cause pneumonia in the post-HCT period. Cancer and immunocompromised patients are presumed to have a higher risk than healthy persons but this has not been well-studied. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a> and  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV</strong> – Before the routine use of prophylactic or pre-emptive anti-CMV regimens, CMV-seropositive allogeneic HCT recipients had a 70 to 80 percent risk of reactivation of this virus, and one-third of these patients developed CMV disease, mostly pneumonia [<a href="#rid50">50</a>]. By comparison, CMV reactivation occurred in only 40 percent of autologous or syngeneic HCT recipients; CMV disease, mainly pneumonia, developed in fewer than 5 percent of these patients [<a href="#rid51">51-53</a>].</p><p></p><p class="bulletIndent1">Currently, CMV pneumonia is infrequent, occurring in fewer than 5 percent of allogeneic HCT recipients. However, since it is treatable and fatal if not treated, evaluation of pneumonia should include tests to exclude CMV as a possible etiology of diffuse pneumonia. The major risk factors for CMV reactivation and disease are GVHD, the use of high-dose glucocorticoids, and prior CMV viremia. The prophylaxis of CMV in HCT recipients is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Cytomegalovirus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated strongyloidiasis</strong> – A rapidly fatal hyperinfection syndrome with disseminated strongyloidiasis and acute respiratory distress syndrome has been reported rarely in HCT recipients [<a href="#rid54">54,55</a>]. The infection develops after cutaneous exposure to contaminated soil.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated toxoplasmosis</strong> – Disseminated toxoplasmosis is rare but is often associated with lung involvement, typically with diffuse infiltrates on imaging [<a href="#rid56">56,57</a>].</p><p></p><p class="headingAnchor" id="H12425073"><span class="h2">Diarrhea</span><span class="headingEndMark"> — </span>Diarrhea during the early postengraftment period can have any of several infectious or noninfectious causes, as outlined below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute GVHD</strong> – During the early postengraftment period, acute GVHD is the most important and a frequent cause of diarrhea. Diarrhea due to gastrointestinal tract GVHD usually occurs in the presence of other manifestations of GVHD, particularly a rash, but it may occur without other organ involvement; lower endoscopy with biopsy is therefore necessary to adequately evaluate this. (See  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV colitis</strong> – CMV colitis is another important consideration that should be investigated by colon biopsy. CMV colitis can occur by itself or can occur concomitantly with gastrointestinal GVHD. Biopsy specimens should be examined for both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Medications are frequent causes of diarrhea during this period. A common medication to cause diarrhea following HCT is oral magnesium, which is given to counter the hypomagnesemia that often occurs with calcineurin inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>C. difficile</em></strong> – An important observation is that <em>C. difficile</em> infection (CDI) in this population is not typically associated with the classic clinical findings, which include mucosal pseudomembranes and elevated leukocyte counts [<a href="#rid27">27,58-60</a>]. Likewise, direct morbidities, such as perforation necessitating surgical resection, are relatively low compared with other hospitalized patients [<a href="#rid27">27</a>]. However, there are reports that CDI is associated with a significant association with gastrointestinal tract GVHD [<a href="#rid27">27,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenovirus</strong> – Adenovirus may reactivate following HCT or be acquired de novo. Reactivation of adenovirus infection is common following HCT but rarely causes severe disease [<a href="#rid61">61</a>]. Adenovirus infection may remain asymptomatic (viremia only) or evolve into various syndromes including upper respiratory tract infection, severe pneumonitis, diarrhea and hemorrhagic colitis, nephritis, and/or hemorrhagic cystitis. Less common manifestations include myocarditis, hepatitis [<a href="#rid62">62</a>], encephalitis, and disseminated disease with multiorgan failure; disseminated disease is rare, occurring in 1 to 7 percent of cases, with reported mortality rates of 8 to 26 percent [<a href="#rid61">61</a>]. The development of adenovirus disease is related to deficiency in adenovirus-specific T cells. Risk factors for adenovirus include severe GVHD requiring high-dose glucocorticoids [<a href="#rid63">63,64</a>], T cell depletion [<a href="#rid65">65,66</a>], <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> or antithymocyte globulin [<a href="#rid67">67</a>], and transplantation with matched unrelated donor or haploidentical grafts or with umbilical cord [<a href="#rid61">61</a>]. Children are more commonly affected than adults [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Hematopoietic cell transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enteric pathogens</strong> – Enteric virus infections among HCT recipients may cause gastroenteritis (coxsackie A [<a href="#rid69">69</a>], rotavirus, norovirus [<a href="#rid70">70,71</a>]), which may be prolonged and cause significant diarrhea [<a href="#rid72">72</a>] but may also involve other organ systems including the lungs, cardiovascular system, and central nervous system. Lymphopenia is thought to be a predisposing factor for these enteric infections [<a href="#rid72">72</a>]. Infection is usually transmitted by the fecal-oral route. Viral infections of the enteric system (eg, coxsackie, echo, and rotaviruses) are most prevalent during the summer and fall months, although rotavirus infections have also been reported during the winter and spring [<a href="#rid72">72</a>]. <em>Cryptosporidium parvum </em>has rarely been reported to cause gastroenteritis after allogeneic T cell–depleted bone marrow transplantation, CD34-positive selected autologous HCT, T cell depletion, or intensive immunosuppression to treat GVHD. The infection may mimic intestinal GVHD [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2710.html" rel="external">"Norovirus"</a>.)</p><p></p><p class="headingAnchor" id="H12425087"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Hepatic abnormalities have many potential causes, including toxicity from medications, acute GVHD, iron overload, hepatitis viruses, other viruses (eg, CMV, Epstein-Barr virus [EBV], human herpesvirus 6 [HHV-6], adenovirus), and chronic disseminated candidiasis (hepatosplenic candidiasis). Hepatic sinusoidal obstruction syndrome (formerly known as venoocclusive disease) generally first manifests during the pre-engraftment period and its onset is rare after day 30. (See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p>GVHD is the primary consideration for hepatic complications during this period. In general, GVHD tends to exhibit a cholestatic pattern rather than a hepatocellular injury pattern, but there is considerable overlap. A liver biopsy is helpful in establishing the diagnosis. If the full constellation typical of acute GVHD (characteristic rash, elevated bilirubin, and diarrhea) is present, biopsy of the most accessible site involved may suffice to establish the diagnosis and abrogate the need for liver biopsy to minimize the risk of biopsy complications.</p><p>Because hepatitis B virus (HBV) may persist as an occult infection among HBsAg-negative patients, it may reactivate following HCT. Intense immunosuppression may cause seroreversion of some patients who are HBsAb positive and HBcAb positive to an HBsAg-positive status, particularly patients with lymphoma [<a href="#rid75">75</a>]. In a study from Korea, 7 of 129 (6 percent) HBsAg-negative patients undergoing autologous HCT seroconverted to a HBsAg-positive status, and 5 (4 percent) developed acute hepatitis [<a href="#rid76">76</a>]. Multiple myeloma also appears to increase the risk of HBV reactivation after autologous HCT [<a href="#rid77">77,78</a>], with a suggested role for the myeloma-active immunomodulatory agents (<a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>) [<a href="#rid78">78</a>].</p><p>The serologic profile of HBV infection may be altered by severe immunosuppression that affects both humoral and cell-mediated control of HBV infection; some HBsAg-positive patients may not develop HBcAb, even in the setting of high-grade HBV replication or in recipients of an HBcAb-positive graft.</p><p>Acute hepatitis after immune reconstitution is the most common manifestation (in approximately 60 percent), particularly with tapering of immunosuppression, although up to 20 percent of patients may not show any signs or symptoms of liver pathology. Long-lasting transaminitis may develop. Reactivation may resolve spontaneously in one-fourth of the cases, while fulminant hepatitis is very rare.</p><p>An important differential diagnosis of viral hepatitis is GVHD because glucocorticoids for a presumptive diagnosis of hepatic GVHD may alleviate the symptoms of both conditions only to lead to increasing viral replication and delayed effective antiviral therapy. Liver biopsy may be required to establish the diagnosis of GVHD.</p><p>With immune reconstitution, HBV may manifest as acute hepatitis with a major increase in HBV viral load. Glucocorticoids should be given if the liver enzymes increase to ≥10 times their upper limits of normal [<a href="#rid79">79</a>]. Such immune "flares" may occur during this period or much later after HCT.</p><p>Reactivation of hepatitis C virus (HCV) occurs in &gt;50 percent of patients undergoing allogeneic HCT. Patients with HCV viremia (HCV ribonucleic acid [RNA] positive) and elevated liver function tests before HCT are at a higher risk for developing severe peritransplant complications. HCV seropositivity is a risk factor for nonrelapse mortality after allogeneic HCT even in patients with normal liver function tests [<a href="#rid80">80,81</a>] and is associated with transient hepatitis in the early post-transplant period; HCV is also a risk factor for hepatic sinusoidal syndrome (SOS) and early cirrhosis [<a href="#rid81">81,82</a>]. However, in one study, HCV infection did not appear to negatively impact 10-year survival [<a href="#rid83">83</a>]. HCV reactivation may manifest as acute hepatitis with a substantial increase in HCV viral load and may be fatal [<a href="#rid79">79</a>].</p><p>The prevention of HBV- and HCV-associated disease following HCT is discussed separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Hepatitis B virus'</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Hepatitis C virus'</a>.)</p><p>Other potential causes of hepatitis are discussed below. (See <a class="local">'Hepatitis'</a> below.)</p><p class="headingAnchor" id="H12425433"><span class="h2">Hemorrhagic cystitis</span><span class="headingEndMark"> — </span>BK polyomavirus (BKPyV) is a common cause of hemorrhagic cystitis during the early postengraftment period. Adenovirus is a less common cause. Even less frequent causes include infectious (eg, cytomegalovirus, JC polyomavirus [JCPyV]) and hematologic (bleeding disorders, thrombocytopenia) causes as well as damage from the conditioning regimen [<a href="#rid31">31,64,84,85</a>]. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Genitourinary tract'</a>.)</p><p>BKPyV-induced hemorrhagic cystitis occurs most commonly at three to six weeks following HCT [<a href="#rid30">30,86</a>]. Hemorrhagic cystitis due to toxicity from the conditioning regimen usually occurs during the pre-engraftment period. (See <a class="local">'Hemorrhagic cystitis'</a> above.)</p><p>BKPyV persistently infects renal tubular epithelial cells and also replicates in urothelial cells. Risk factors for BKPyV-associated hemorrhagic cystitis include a myeloablative conditioning regimen in the setting of human leukocyte antigen (HLA) mismatch, particularly from unrelated donor or umbilical cord blood HCT [<a href="#rid87">87,88</a>]. Conditioning with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> has also been reported as a risk factor [<a href="#rid89">89</a>]. The complex interaction between BKPyV replication, the intensity of the conditioning regimen, and donor type was illustrated in a study in which recipients of haploidentical or umbilical cord blood grafts with myeloablative conditioning who had a positive urine BKPyV polymerase chain reaction (PCR) pretransplant had a significantly higher risk of developing hemorrhagic cystitis (58 percent) than all other recipients (7 percent) [<a href="#rid88">88</a>]. The possible role of GVHD as a risk factor has been suggested but is not clearly established [<a href="#rid87">87,88</a>].</p><p>BK viruria (BKPyV replication detected in urine) occurs in approximately half of allogeneic and fewer than 10 percent of autologous HCT recipients and has been associated with hemorrhagic cystitis [<a href="#rid84">84,86,90-92</a>]. However, the detection of BK viruria is not sufficient to establish the diagnosis of BKPyV-associated hemorrhagic cystitis. Detection of BKPyV deoxyribonucleic acid (DNA) in plasma also appears to be a marker of BKPyV-associated hemorrhagic cystitis in HCT recipients. Levels of BK viremia &gt;10,000 copies/mL are thought to predict renal and urologic outcomes in HCT recipients [<a href="#rid93">93</a>].<em> </em>In a case-control study, 30 cases of hemorrhagic cystitis with documented BK viruria were compared with matched controls and weekly plasma samples were tested for BKPyV DNA by PCR [<a href="#rid92">92</a>]. BK viremia detected before or during the disease was independently associated with hemorrhagic cystitis. Cases of BKPyV-associated hemorrhagic cystitis had a significantly higher peak of BK plasma viral load and long-lasting BK viremia. (See  <a class="medical medical_review" href="/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections", section on 'Hemorrhagic cystitis'</a>.)</p><p>The clinical manifestations of BKPyV-associated hemorrhagic cystitis after HCT range in severity and may include cystitis (dysuria, urinary urgency, lower abdominal discomfort), macrohematuria with or without clots, renal failure due to obstruction, and, rarely, life-threatening bleeding requiring urologic interventions including cystectomy.</p><p>Ureteral stenosis due to BKPyV has been reported rarely in HCT recipients [<a href="#rid94">94,95</a>]. In one report, an HCT recipient with BKPyV infection developed hemorrhagic cystitis followed by bilateral ureteral stenosis, suggesting that BKPyV can cause an ascending infection [<a href="#rid94">94</a>]. BKPyV viruria has been associated with a higher risk of renal failure, which has been proven by biopsy in occasional cases [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H12425448"><span class="h2">Encephalitis</span><span class="headingEndMark"> — </span>Several pathogens can cause encephalitis, particularly viruses such as HHV-6, but also other pathogens such as <em>Toxoplasma gondii</em>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human herpesvirus 6</strong> – HHV-6 reactivation occurs in 30 to 50 percent of patients undergoing allogeneic HCT [<a href="#rid97">97-100</a>], with encephalitis occurring in only a small subset of these patients. HHV-6 reactivation often manifests as HHV-6 viremia and typically occurs between two and four weeks after transplantation. HHV-6 infection in HCT recipients is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16146.html" rel="external">"Human herpesvirus 6 infection in hematopoietic cell transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex virus (HSV)</strong> – HSV infections should be considered in patients presenting with encephalitis [<a href="#rid101">101,102</a>], although today it would be a rare cause. HSV reactivation is usually prevented with <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> or <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> prophylaxis, but it can occur following discontinuation of antiviral prophylaxis or in patients infected with resistant isolates. (See  <a class="medical medical_review" href="/d/html/8278.html" rel="external">"Herpes simplex virus type 1 encephalitis"</a> and  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Herpes simplex virus'</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Varicella-zoster virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella-zoster virus (VZV)</strong> – VZV reactivation usually occurs during the late postengraftment period, but it should be considered in patients presenting with encephalitis even during the early postengraftment period. (See <a class="local">'Encephalitis and meningitis'</a> below and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Varicella-zoster virus'</a> and  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Encephalitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus</strong> – CMV has been reported rarely as a cause of encephalitis in HCT recipients [<a href="#rid101">101,103,104</a>]. Risk factors for CMV disease of the central nervous system include severe and prolonged T cell immunodeficiency (T cell depletion, antithymocyte globulin, umbilical cord blood transplant), a history of recurrent CMV viremia treated with multiple courses of pre-emptive antiviral therapy, and ganciclovir-resistant CMV infection [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Cytomegalovirus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus</strong> – Disease caused by EBV most commonly occurs in the late postengraftment phase, although the infection can be detected prior to day 100 among patients treated with T cell-depleted grafts or anti-T cell monoclonal antibodies such as <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid105">105</a>]. Post-transplant lymphoproliferative disorder can manifest as fever, lymphadenopathy, and/or extranodal lymphomatous proliferation in various organs (liver, gastrointestinal tract, lungs, central nervous system, and bone marrow) and is characterized by monoclonal B cell proliferation with malignant cytogenetic abnormalities and immunoglobulin gene rearrangements. (See  <a class="medical medical_review" href="/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JC polyomavirus</strong> – JCPyV can replicate in the central nervous system, where it can lead to severe demyelination in subcortical areas (called progressive multifocal leukoencephalopathy [PML]) or in the cerebellum (called granule cell neuronopathy). PML usually presents with subacute neurologic deficits including seizures, altered mental status, visual symptoms related to visual field defects (hemianopia and diplopia), weakness, hemiparesis or monoparesis, and/or ataxia [<a href="#rid106">106</a>]. The diagnosis should be suspected when neuroimaging reveals a multifocal process limited to the white matter that does not exhibit pronounced contrast enhancement or a mass effect nor conform to vascular territories. Although brain biopsy is the gold standard for diagnosis of PML, it is associated with significant morbidity and even mortality. In most cases, a laboratory-confirmed diagnosis can be made using PCR for JCPyV DNA in the cerebrospinal fluid (CSF) in patients who exhibit characteristic neurologic and neuroimaging features [<a href="#rid107">107</a>]. The median time to the first symptoms of PML following HCT is 11 months, with a median survival of approximately 20 months following symptom onset [<a href="#rid108">108</a>]. Risk factors for PML in HCT recipients include therapy with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> [<a href="#rid109">109,110</a>] or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid111">111,112</a>], particularly in patients with very low CD4+ T cell counts [<a href="#rid112">112</a>]. PML is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>West Nile virus</strong> – West Nile virus infections have been reported among HCT recipients and occur during late summer and fall [<a href="#rid113">113,114</a>]. The infection is acquired from mosquito bites (median incubation of two weeks) and rarely from transfusion of a blood product or from an infected graft (within four weeks of transfusion or receipt of the graft). The presentation of West Nile virus infection in HCT recipients includes fever, lethargy, and rapidly progressive bilateral extremity weakness leading to acute flaccid paralysis (severe quadriparesis or quadriplegia with hypotonia and loss of reflexes). Meningitis and/or encephalitis are other presentations of West Nile virus infection in HCT recipients. Most patients develop an encephalopathy. The diagnosis is made by the combination of the clinical findings and detection of West Nile virus from blood, tissue, or cerebrospinal fluid samples using PCR or rarely with viral culture [<a href="#rid114">114</a>]. Detection of West Nile virus immunoglobulin (Ig)M antibodies in CSF is not a sensitive test in HCT recipients because of their severe immunodeficiency [<a href="#rid114">114</a>]. West Nile virus is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1304.html" rel="external">"Epidemiology and pathogenesis of West Nile virus infection"</a> and  <a class="medical medical_review" href="/d/html/1273.html" rel="external">"Clinical manifestations and diagnosis of West Nile virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenovirus</strong> – Adenovirus has been reported as a rare cause of encephalitis in HCT recipients [<a href="#rid102">102</a>]. (See <a class="local">'Diarrhea'</a> above and  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Nervous system'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxoplasmosis</strong> – Cerebral toxoplasmosis typically develops between days 60 and 150 after allogeneic HCT. Patients may have manifestations of increased intracranial pressure, neurologic deficits, and/or seizures, all of which are caused by an intracerebral abscess that can be identified by magnetic resonance imaging of the brain. Other manifestations of toxoplasmosis in HCT recipients include Guillain-Barré syndrome, cutaneous infections, hematologic complications such as graft failure [<a href="#rid115">115</a>] or hemophagocytic syndrome [<a href="#rid116">116</a>], chorioretinitis [<a href="#rid117">117</a>], or disseminated disease [<a href="#rid56">56</a>]. Risk factors include positive serology, no <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) prophylaxis, severe GVHD, ablative conditioning regimen, T cell depletion, or use of antithymocyte globulin (ATG) [<a href="#rid118">118-121</a>].</p><p></p><p>Viral encephalitis (including causes not discussed above, such as Eastern equine encephalitis and other arboviruses) is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6042.html" rel="external">"Acute viral encephalitis in children: Clinical manifestations and diagnosis"</a>.)</p><p>In addition to infectious causes, the following noninfectious causes can result in encephalopathy:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">Fludarabine</a><strong> toxicity</strong> – Delayed cortical damage from fludarabine may be a cause of encephalopathy. This may be seen in the early or late postengraftment period and typically progresses over time. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Purine analogs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posterior reversible encephalopathy syndrome (PRES)</strong> – Calcineurin inhibitors are associated with PRES [<a href="#rid122">122</a>]. PRES may present as seizures, altered sensorium, visual symptoms or other manifestation, and can present in either the early or late postengraftment periods. (See  <a class="medical medical_review" href="/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H3926190"><span class="h1">LATE POSTENGRAFTMENT PERIOD</span><span class="headingEndMark"> — </span>Patients remain at high risk for infections even late after transplantation and may require prolonged follow-up. Late infectious complications are typically only seen among allogeneic recipients with specific risk factors including [<a href="#rid123">123</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive chronic graft-versus-host disease (GVHD) and intensive therapy for GVHD, resulting in delayed immune reconstitution (eg, cellular and humoral immune dysfunction, hyposplenism, and decrease in opsonization)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus (CMV)-seronegative donor status and -seropositive recipient status (CMV D-/R+)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose (myeloablative) and radiation-based conditioning regimens</p><p></p><p>Sinusitis, upper respiratory tract infections, pneumonia, and meningitis are frequently caused by the encapsulated bacteria (<em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, <em>Neisseria meningitidis</em>) during the late postengraftment period [<a href="#rid123">123-126</a>]. Late bacteremia is also common after allogeneic HCT and is typically caused by encapsulated bacteria [<a href="#rid124">124-126</a>], staphylococci, and gram-negative bacteria such as <em>Pseudomonas</em> spp [<a href="#rid127">127</a>]. Patients with chronic GVHD are particularly vulnerable due to poor opsonization, hypogammaglobulinemia, and hyposplenism.</p><p>In a study of 196 long-term survivors after human leukocyte antigen (HLA)-matched related hematopoietic cell transplantation (HCT; median follow-up of eight years), infection was the cause of death of 19 of the 30 patients who died beyond the first year [<a href="#rid123">123</a>]. Late bacterial infections (mostly sepsis and pneumonia) occurred in 30 patients, yielding an eight-year cumulative incidence of 15 percent. Eighteen pathogens were identified, including <em>S. pneumoniae</em> (six infections, of which three were meningitis), <em>Salmonella</em> spp (three infections), <em>S. aureus</em> (two infections), <em>H. influenzae</em>, <em>C. difficile</em>, and others. Most infections developed during the second year after HCT while patients were receiving <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> prophylaxis. Patients were vaccinated according to the European recommendations, including against <em>S. pneumoniae</em> [<a href="#rid128">128</a>]. Extensive chronic GVHD (hazard ratio [HR] 2.9), CMV D-/R+ serostatus (HR 2.5), and an irradiation-based conditioning regimen (HR 3.1) were independent predictors of late bacterial infections [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H1909225389"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>The spectrum of infectious and noninfectious etiologies for pneumonia is mostly similar to the spectrum during the early postengraftment period. Diffuse pneumonias are evenly divided between noninfectious (cryptogenic organizing pneumonia) and infectious (CMV, respiratory viruses, <em>Pneumocystis </em>pneumonia [PCP]). Nodular pneumonias are mostly infectious, most commonly due to gram-positive or gram-negative bacteria but occasionally due to <em>Aspergillus</em> spp, other molds, or <em>Nocardia</em>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchiolitis obliterans/bronchiolitis obliterans syndrome and cryptogenic organizing pneumonia</strong> – Idiopathic pneumonia due to toxicity from the conditioning regimen is no longer a major concern during the late postengraftment period. However, bronchiolitis obliterans/bronchiolitis obliterans syndrome (BO/BOS) and cryptogenic organizing pneumonia (COP; formerly known as bronchiolitis obliterans with organizing pneumonia [BOOP]), which are associated with chronic GVHD, are major concerns. BO and COP manifest clinically by progressive dyspnea and cough; each entity has characteristic radiographic findings. Aggressive diagnosis and prompt treatment are necessary to reduce the threat of progressive respiratory insufficiency. When these diagnoses are being considered, infections should be searched for as they can present in a similar way and may also precipitate or complicate both processes. BO/BOS and COP are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'</a> and  <a class="medical medical_review" href="/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a> and  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Organizing pneumonia'</a> and  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcus</strong> – The risk of pneumococcal infection is greater among patients undergoing therapy for extensive chronic GVHD [<a href="#rid126">126,129</a>] and is attributed to immunoglobulin (Ig) deficiency (usually in subclasses IgG2 and IgG4) [<a href="#rid130">130</a>] and hyposplenism [<a href="#rid131">131,132</a>]. In a review of 47 HCT recipients who developed 54 pneumococcal infections, 50 infections occurred late at a mean of 473 days after transplantation [<a href="#rid126">126</a>]. Bacteremic pneumonia was the most common manifestation, but either isolated pneumonia or bacteremia also occurred. Infection occurred in five patients despite pneumococcal vaccination. (See  <a class="medical medical_review" href="/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus</strong> – With the use of pre-emptive anti-CMV therapy, late CMV infection and disease (after day 100) has become a more significant problem following allogeneic HCT and is associated with nonrelapse mortality [<a href="#rid133">133</a>]. Overall, 15 to 30 percent and 6 to 18 percent of allogeneic HCT recipients develop late CMV infection and disease, respectively [<a href="#rid133">133-136</a>]. Factors predictive of late CMV disease include CMV-seronegative donor graft, delayed or no reconstitution of CMV-specific T cell responses as a result of mismatched/unrelated transplant, use of anti-CMV prophylaxis, and/or early CMV reactivation (before day 100) [<a href="#rid133">133,136-138</a>]. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Cytomegalovirus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Nocardia</em></strong> – <em>Nocardia</em> can cause nodular pulmonary infiltrates during this period (and sometimes additionally skin nodules and cerebral infarcts) and can be indistinguishable from invasive pulmonary aspergillosis [<a href="#rid139">139</a>]. (See  <a class="medical medical_review" href="/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal pneumonia</strong> – Causes of fungal pneumonia include <em>Aspergillus</em> spp and the agents of mucormycosis. During this period, fungal pneumonia is most common in those receiving glucocorticoids for GVHD [<a href="#rid1">1,36</a>]. (See  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Pneumocystis</em></strong> – Late <em>Pneumocystis</em> pneumonia may occur among patients who are no longer receiving <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis [<a href="#rid40">40</a>]. This is most common in patients receiving prolonged corticosteroids for chronic GVHD. (See  <a class="medical medical_review" href="/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transplant lymphoproliferative disease</strong> – Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) can present as pulmonary nodules. The median time to onset is between three to five months following transplantation, although it has occurred prior to day 100 among patients at high risk for PTLD [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycobacteria</strong> — Mycobacterial infections in transplant recipients are rare, occurring in 1 to 3 percent of allogeneic and 0.2 percent of autologous HCT recipients [<a href="#rid140">140-144</a>]. Infection can arise due to reactivation or new exposure. Tuberculosis (TB) typically occurs late after engraftment (&gt;100 days with a few cases diagnosed four years after HCT) and manifests with fever, cough, weight loss, and various types of pulmonary infiltrates. Extrapulmonary TB occurs in approximately 15 percent of patients and may involve the kidneys, bone marrow, central nervous system, and joints [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1">Nontuberculous mycobacteria (NTM) are more common causes of mycobacterial infections in HCT recipients in developed countries. Extrapulmonary disease, such as bloodstream, catheter-related, soft tissue, bone, and joint infections, is more common with NTM [<a href="#rid140">140-142</a>]. In a review of infections among HCT recipients, the incidence of NTM infection ranged from 0.4 to 4.9 percent with a median time of onset of 4.6 months [<a href="#rid146">146</a>]. GVHD appears to be a predisposing factor for NTM infections.</p><p></p><p class="bulletIndent1">More than one-third of patients with NTM disease have a central venous catheter-related infection (bacteremia, exit site, or tunnel infection), most of which are caused by the rapidly growing NTM (eg, <em>Mycobacterium fortuitum</em>, <em>M. abscessus</em>, <em>M. chelonae</em>) [<a href="#rid146">146</a>]. Infection with the rapidly growing NTM is generally diagnosed using routine blood cultures. Pneumonia and disseminated disease are usually caused by <em>Mycobacterium avium</em> complex or <em>M. haemophilum</em>, whereas cutaneous lesions are seen with <em>M. haemophilum</em>, which may also cause disseminated, osteoarticular, and catheter-related infections. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p></p><p class="headingAnchor" id="H12425583"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Hepatic abnormalities may occur from multiple causes similar with those in the early postengraftment period, including toxicity from medications, chronic GVHD, iron overload, hepatitis viruses, other viruses (eg, CMV, EBV, human herpesvirus 6 [HHV-6], adenovirus), and chronic disseminated candidiasis (hepatosplenic candidiasis). As immune reconstitution progresses with tapering of the immunosuppressive regimen, hepatic injury from reactivation of hepatitis viruses may manifest. (See <a class="local">'Hepatitis'</a> above.)</p><p>Among the hepatitis viruses, not only hepatitis A, B, and C but also hepatitis E, can cause hepatitis in HCT recipients and has been reported to cause both acute and chronic disease in these hosts [<a href="#rid147">147</a>]. (See  <a class="medical medical_review" href="/d/html/3677.html" rel="external">"Hepatitis E virus infection"</a>.)</p><p>Isolated varicella-zoster virus (VZV) reactivation in the absence of skin lesions involving liver, pancreas, or serosa of the bowel wall can present as severe hepatocellular injury, abdominal pain, or ileus in patients not receiving <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> prophylaxis [<a href="#rid148">148</a>]. This can lead to severe hepatocellular injury, bowel perforation or obstruction, or acute abdomen, and one should presumptively treat for VZV while the diagnostic evaluation proceeds.</p><p>Herpes simplex virus (HSV) can also be a rare cause of hepatitis. (See  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Hepatitis'</a>.)</p><p class="headingAnchor" id="H12425590"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>A variety of skin rashes and lesions are seen in patients with chronic GVHD. Cutaneous and subcutaneous nodules can result from disseminated fungal or bacterial infections. Labial and genital ulcers and vesicles can occur from recurrent HSV infections.</p><p>VZV typically presents with a characteristic dermatomal distribution of vesicular lesions. The incidence of VZV reactivation is approximately equal among allogeneic and autologous HCT recipients (20 to 40 percent). VZV infection tends be more common among children (up to 90 percent by year 1) and to occur earlier post-transplantation (median 100 days) [<a href="#rid149">149</a>]. In one study, VZV accounted for the majority of late infections (&gt;1 year) following allogeneic HCT with an eight-year cumulative incidence of 27 percent [<a href="#rid123">123</a>]. Infection typically occurs during the first six to nine months (80 percent during the first year) and may be associated with complications including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous dissemination – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Postherpetic neuralgia – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Scarring – 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial superinfection – 15 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Death – 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system manifestations – &lt;2 percent</p><p></p><p>Dissemination following allogeneic HCT is more common than after autologous HCT (45 versus 25 percent) [<a href="#rid150">150</a>]. In addition to the skin, dissemination may involve the lungs, liver, and the central nervous system manifesting as meningoencephalitis [<a href="#rid151">151,152</a>]. In HCT recipients, VZV lesions last longer (10 to 14 days) and heal more slowly (3 to 4 weeks) than in healthy adults [<a href="#rid153">153</a>].</p><p>Immunocompromised patients uncommonly develop varicella-like skin lesions without a primary dermatomal eruption, a syndrome termed atypical generalized zoster [<a href="#rid153">153</a>]. VZV infection without a skin rash occurs rarely after HCT [<a href="#rid154">154,155</a>]. Thrombocytopenia and disseminated intravascular coagulation have also been reported. Durable immunity seems to develop following this type of infection, since fewer than 5 percent of patients have a second episode [<a href="#rid153">153</a>].</p><p>The risk factors for VZV reactivation include VZV seropositivity, VZV infection prior to HCT, extensive therapy for the underlying cancer before HCT, hematologic cancer other than chronic myelogenous leukemia, intensive immunosuppression (pretransplant irradiation, post-transplant use of antithymocyte globulin), and severe and extensive chronic GVHD requiring intensive immunosuppression [<a href="#rid151">151,152,156</a>]. VZV may also occur in patients without GVHD (typically after discontinuation of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>). VZV-specific cell-mediated immune responses (usually suppressed after HCT) inversely correlate with the risk of VZV infection. By contrast, no correlation has been found between the level of pretransplant VZV IgG antibodies and post-transplant reactivation [<a href="#rid157">157</a>].</p><p class="headingAnchor" id="H12425623"><span class="h2">Encephalitis and meningitis</span><span class="headingEndMark"> — </span>The same causes of these syndromes seen in the early postengraftment period may occur during the late postengraftment period. (See <a class="local">'Encephalitis'</a> above.)</p><p>In addition, listeriosis, although uncommon after HCT, usually develops during the late postengraftment phase [<a href="#rid158">158</a>]. Infection with <em>Listeria monocytogenes</em> almost always involves the bloodstream with a high incidence of meningitis (two-thirds of patients) and other forms of parenchymal brain infection including encephalitis, cerebritis, and brain abscess and very rarely brainstem infection (rhombencephalitis) [<a href="#rid159">159</a>]. The use of<em> </em><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis for <em>Pneumocystis </em>prophylaxis and adherence to food safety guidelines usually protect against listeriosis. (See  <a class="medical medical_review" href="/d/html/1277.html" rel="external">"Clinical manifestations and diagnosis of Listeria monocytogenes infection", section on 'Central nervous system infection'</a>.)</p><p><em>Cryptococcus</em> is an infrequent cause of leptomeningitis during the late postengraftment period. (See  <a class="medical medical_review" href="/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p>VZV has been reported to cause meningoencephalitis rarely during the late postengraftment period in patients with chronic GVHD [<a href="#rid102">102,160,161</a>]. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Encephalitis'</a>.)</p><p class="headingAnchor" id="H12425630"><span class="h2">Diarrhea</span><span class="headingEndMark"> — </span>The causes are similar with those in the early postengraftment period. Of note, diarrhea is much less commonly a manifestation of chronic GVHD compared with acute GVHD; infectious etiologies should therefore be vigorously pursued, and the spectrum of infectious agents is similar with the earlier period. In addition, late manifestations of EBV may include gastrointestinal tract involvement with a risk for bleeding and perforation. (See <a class="local">'Diarrhea'</a> above.)</p><p class="headingAnchor" id="H1806765785"><span class="h2">Fever</span><span class="headingEndMark"> — </span>There are multiple possible causes of fever during the late postengraftment period, including GVHD, sinopulmonary infection, central venous line–associated infection, fungal infection, and mycobacterial infection. One-third of patients with NTM disease have a central venous catheter–related infection (bacteremia, exit site or tunnel infection), most of which are caused by the rapidly growing NTM (eg, <em>M. fortuitum</em>, <em>M. abscessus</em>, <em>M. chelonae</em>) [<a href="#rid146">146</a>].</p><p>A variety of viruses may cause fever, including CMV, EBV, HHV-6, adenovirus, West Nile virus, adenovirus, and others.</p><p>EBV reactivation may involve episomal, lytic, or both modes of genome replication [<a href="#rid162">162</a>] and may originate from B cells from the donor and/or recipient. Most patients with EBV reactivation remain asymptomatic. Three types of EBV-related lymphoproliferative disease occur in HCT recipients [<a href="#rid105">105</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An infectious mononucleosis–type acute illness that develops two to eight weeks after induction, characterized by polyclonal B cell proliferation without features of malignant transformation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar clinical disorder but with features of early malignant transformation, such as cytogenetic abnormalities and immunoglobulin gene rearrangements</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-transplant lymphoproliferative disease – A more severe clinical presentation with fever, lymphadenopathy, and/or extranodal lymphomatous proliferation in various organs (liver, gastrointestinal tract, lungs, central nervous system, bone marrow),which is characterized by monoclonal B cell proliferation with malignant cytogenetic abnormalities and immunoglobulin gene rearrangements</p><p></p><p>The rate of PTLD varies greatly according to the type of HCT. The risk is greatest in patients with profound T cell cytopenia (eg, after T cell depletion, use of anti-T cell antibodies, umbilical cord blood transplants, HLA-mismatched transplants) [<a href="#rid17">17,163-165</a>]. Donor/recipient EBV serologic mismatch, prior EBV reactivation, and splenectomy are additional risk factors for PTLD, and the number of risk factors present incrementally increases the risk [<a href="#rid105">105,166</a>].</p><p>The pace of PTLD ranges from indolent to fulminant, and the extent of disease varies from localized nodular lesions to widely disseminated disease [<a href="#rid105">105,167</a>]. PTLD is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a> and  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p class="headingAnchor" id="H2767336154"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/89369.html" rel="external">"Patient education: Neutropenia and fever in people being treated for cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3926197"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timeline for infections</strong> − Infectious pathogens and infectious syndromes vary during the different phases following HCT; the risk of infection is higher following allogeneic HCT  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 2</a>) compared with autologous HCT  (<a class="graphic graphic_figure graphicRef64491" href="/d/graphic/64491.html" rel="external">figure 3</a>). (See <a class="local">'Timeline for infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-engraftment period</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the pre-engraftment period, neutropenic fever is frequent, and the causes, evaluation, and management strategies are the same as with high-risk non-HCT patients. (See <a class="local">'Neutropenic fever'</a> above and  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a> and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea is commonly caused by <em>Clostridioides</em> <em>difficile</em> or by neutropenic enterocolitis (typhlitis), but it may also be due to noninfectious causes such as mucosal injury due to the conditioning regimen or medication effects. (See <a class="local">'Diarrhea'</a> above and  <a class="medical medical_review" href="/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a> and  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2690.html" rel="external">"Neutropenic enterocolitis (typhlitis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse pulmonary infiltrates during the pre-engraftment period are mostly due to noninfectious causes, such as pulmonary edema or lung damage resulting from the conditioning regimen, but respiratory viral infections can occasionally occur. Nodular pneumonias are mostly infectious, most commonly due to gram-positive or gram-negative bacteria but occasionally due to <em>Aspergillus</em> spp. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postengraftment period </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the early postengraftment period, diffuse pneumonias are evenly divided between noninfectious (conditioning regimen toxicity) and infectious (cytomegalovirus [CMV], respiratory viruses, <em>Pneumocystis</em> pneumonia [PCP]). Nodular pneumonias are mostly infectious, evenly divided between bacteria (gram positive and gram negative) and <em>Aspergillus</em> spp (or, less commonly, other molds). (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea may be due to medication effects, graft-versus-host disease (GVHD), <em>C. difficile</em>, or CMV. (See <a class="local">'Diarrhea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatocellular injury may be due to medication toxicity, GVHD, or reactivation of hepatitis for patients with prior hepatitis. (See <a class="local">'Hepatitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Encephalitis may be due to drug toxicity or several viral pathogens, including human herpes virus 6, CMV, varicella-zoster virus (VZV), herpes simplex virus, JC polyomavirus, West Nile virus, or Epstein-Barr virus. (See <a class="local">'Encephalitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemorrhagic cystitis is most commonly due to BK polyomavirus. Adenovirus is a less common cause. Even less frequent causes include infectious (other viruses [CMV, JC polyomavirus] and hematologic causes (bleeding disorders, thrombocytopenia, possibly GVHD) as well as damage from the conditioning regimen. (See <a class="local">'Hemorrhagic cystitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late postengraftment period </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the late postengraftment period, sinopulmonary infections, especially in patients with chronic GVHD, are frequently caused by encapsulated bacteria. (See <a class="local">'Late postengraftment period'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse pneumonias are evenly divided between noninfectious (cryptogenic organizing pneumonia) and infectious (CMV, respiratory viruses, PCP). Nodular pneumonias are mostly infectious, most commonly due to gram-positive or gram-negative bacteria but occasionally due to <em>Aspergillus</em> spp, other molds, or <em>Nocardia</em>. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VZV infection frequently occurs late after HCT. (See <a class="local">'Skin lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and prevention of infections</strong> − Evaluation for infection before HCT and prevention of infection in HCT recipients are discussed separately. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H695125"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Elias Anaissie and Dr. Kieren A Marr, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49:1211.</a></li><li><a class="nounderline abstract_t">Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.</a></li><li><a class="nounderline abstract_t">Mullighan CG, Heatley SL, Danner S, et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 2008; 112:2120.</a></li><li><a class="nounderline abstract_t">Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.</a></li><li><a class="nounderline abstract_t">Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370:421.</a></li><li><a class="nounderline abstract_t">Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394.</a></li><li><a class="nounderline abstract_t">Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011; 203:736.</a></li><li><a class="nounderline abstract_t">Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis 2014; 59:569.</a></li><li><a class="nounderline abstract_t">Zaia JA, Sun JY, Gallez-Hawkins GM, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:315.</a></li><li><a class="nounderline abstract_t">Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.</a></li><li><a class="nounderline abstract_t">Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011; 19:1001.</a></li><li><a class="nounderline abstract_t">Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004; 12:555.</a></li><li><a class="nounderline abstract_t">Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24:4129.</a></li><li><a class="nounderline abstract_t">Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273.</a></li><li><a class="nounderline abstract_t">Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110:4606.</a></li><li><a class="nounderline abstract_t">Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</a></li><li><a class="nounderline abstract_t">Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93:467.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323.</a></li><li><a class="nounderline abstract_t">Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.</a></li><li><a class="nounderline abstract_t">Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.</a></li><li><a class="nounderline abstract_t">Wingard JR. Infections in allogeneic bone marrow transplant recipients. Semin Oncol 1993; 20:80.</a></li><li><a class="nounderline abstract_t">Prentice HG, Hann IM. Antiviral therapy in the immunocompromised patient. Br Med Bull 1985; 41:367.</a></li><li><a class="nounderline abstract_t">Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000; 26:871.</a></li><li><a class="nounderline abstract_t">Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37:517.</a></li><li><a class="nounderline abstract_t">Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54:1053.</a></li><li><a class="nounderline abstract_t">Dubberke ER, Reske KA, Olsen MA, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis 2018; 20:e12855.</a></li><li><a class="nounderline abstract_t">Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood 2012; 120:1791.</a></li><li><a class="nounderline abstract_t">Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:471.</a></li><li><a class="nounderline abstract_t">Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13:1103.</a></li><li><a class="nounderline abstract_t">Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7:11.</a></li><li><a class="nounderline abstract_t">Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.</a></li><li><a class="nounderline abstract_t">Jantunen E, Ruutu P, Piilonen A, et al. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 26:759.</a></li><li><a class="nounderline abstract_t">Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.</a></li><li><a class="nounderline abstract_t">Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827.</a></li><li><a class="nounderline abstract_t">Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.</a></li><li><a class="nounderline abstract_t">Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 Suppl 1:S43.</a></li><li><a class="nounderline abstract_t">De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36:879.</a></li><li><a class="nounderline abstract_t">Roblot F, Imbert S, Godet C, et al. Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 2004; 36:848.</a></li><li><a class="nounderline abstract_t">Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29:1467.</a></li><li><a class="nounderline abstract_t">Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant 2016; 51:573.</a></li><li><a class="nounderline abstract_t">Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005; 11:521.</a></li><li><a class="nounderline abstract_t">Vasconcelles MJ, Bernardo MV, King C, et al. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000; 6:35.</a></li><li><a class="nounderline abstract_t">Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300.</a></li><li><a class="nounderline abstract_t">Parody R, Rabella N, Martino R, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol 2007; 82:807.</a></li><li><a class="nounderline abstract_t">Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573.</a></li><li><a class="nounderline abstract_t">Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139.</a></li><li><a class="nounderline abstract_t">Gluckman E, Traineau R, Devergie A, et al. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 1992; 64 Suppl:A158.</a></li><li><a class="nounderline abstract_t">Wingard JR, Chen DY, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:1432.</a></li><li><a class="nounderline abstract_t">Ljungman P, Biron P, Bosi A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 13:209.</a></li><li><a class="nounderline abstract_t">Boeckh M, Gooley TA, Reusser P, et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172:939.</a></li><li><a class="nounderline abstract_t">Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.</a></li><li><a class="nounderline abstract_t">Qazilbash MH, Ueno NT, Hosing C, et al. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38:393.</a></li><li><a class="nounderline abstract_t">Schmidt M, Sonneville R, Schnell D, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin Infect Dis 2013; 57:1535.</a></li><li><a class="nounderline abstract_t">Busemann C, Ribback S, Zimmermann K, et al. Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience. Ann Hematol 2012; 91:1081.</a></li><li><a class="nounderline abstract_t">Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44:74.</a></li><li><a class="nounderline abstract_t">Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25:E82.</a></li><li><a class="nounderline abstract_t">Trifilio S, Helenowski I, Giel M, et al. Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18:1385.</a></li><li><a class="nounderline abstract_t">Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116:5476.</a></li><li><a class="nounderline abstract_t">Bertheau P, Parquet N, Ferchal F, et al. Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17:295.</a></li><li><a class="nounderline abstract_t">Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619.</a></li><li><a class="nounderline abstract_t">La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32:871.</a></li><li><a class="nounderline abstract_t">Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92:1254.</a></li><li><a class="nounderline abstract_t">Lee YJ, Chung D, Xiao K, et al. Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. Biol Blood Marrow Transplant 2013; 19:387.</a></li><li><a class="nounderline abstract_t">Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36:1001.</a></li><li><a class="nounderline abstract_t">Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 2012; 14:555.</a></li><li><a class="nounderline abstract_t">Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306:1010.</a></li><li><a class="nounderline abstract_t">Roddie C, Paul JP, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49:1061.</a></li><li><a class="nounderline abstract_t">Schwartz S, Vergoulidou M, Schreier E, et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 2011; 117:5850.</a></li><li><a class="nounderline abstract_t">Liakopoulou E, Mutton K, Carrington D, et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36:691.</a></li><li><a class="nounderline abstract_t">Nachbaur D, Kropshofer G, Feichtinger H, et al. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant 1997; 19:1261.</a></li><li><a class="nounderline abstract_t">Müller CI, Zeiser R, Grüllich C, et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. Transplantation 2004; 77:1478.</a></li><li><a class="nounderline abstract_t">Park SC, Jeong SH, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol 2008; 80:960.</a></li><li><a class="nounderline abstract_t">Uhm JE, Kim K, Lim TK, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:463.</a></li><li><a class="nounderline abstract_t">Ceneli O, Ozkurt ZN, Acar K, et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010; 16:1765.</a></li><li><a class="nounderline abstract_t">Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23:421.</a></li><li><a class="nounderline abstract_t">Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31:295.</a></li><li><a class="nounderline abstract_t">Ramos CA, Saliba RM, de Pádua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94:249.</a></li><li><a class="nounderline abstract_t">Peffault de Latour R, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 2008; 48:1008.</a></li><li><a class="nounderline abstract_t">McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51:1450.</a></li><li><a class="nounderline abstract_t">Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893.</a></li><li><a class="nounderline abstract_t">Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis 2004; 39:1861.</a></li><li class="breakAll">Hirsch HH, Pergam SA. Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation. In: Thomas' Hematopoietic Cell Transplantation, 5th ed, Forman SJ, Negrin RS, Antin JH, et al (Eds), Wiley-Blackwell, Chichester, West Sussex 2016.</li><li><a class="nounderline abstract_t">Giraud G, Priftakis P, Bogdanovic G, et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 2008; 41:737.</a></li><li><a class="nounderline abstract_t">Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011; 31:939.</a></li><li><a class="nounderline abstract_t">Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010; 95:1183.</a></li><li><a class="nounderline abstract_t">Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009; 11:413.</a></li><li><a class="nounderline abstract_t">Fioriti D, Degener AM, Mischitelli M, et al. BKV infection and hemorrhagic cystitis after allogeneic bone marrow transplant. Int J Immunopathol Pharmacol 2005; 18:309.</a></li><li><a class="nounderline abstract_t">Cesaro S, Facchin C, Tridello G, et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:363.</a></li><li><a class="nounderline abstract_t">Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005; 106:1130.</a></li><li><a class="nounderline abstract_t">Haines HL, Laskin BL, Goebel J, et al. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1512.</a></li><li><a class="nounderline abstract_t">Hwang YY, Sim J, Leung AY, et al. BK virus-associated bilateral ureteric stenosis after haematopoietic SCT: viral kinetics and successful treatment. Bone Marrow Transplant 2013; 48:745.</a></li><li><a class="nounderline abstract_t">Khan H, Oberoi S, Mahvash A, et al. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 2011; 17:1551.</a></li><li><a class="nounderline abstract_t">O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant 2009; 15:1038.</a></li><li><a class="nounderline abstract_t">Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000; 111:774.</a></li><li><a class="nounderline abstract_t">Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis 2002; 185:847.</a></li><li><a class="nounderline abstract_t">Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40:932.</a></li><li><a class="nounderline abstract_t">Hentrich M, Oruzio D, Jäger G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005; 128:66.</a></li><li><a class="nounderline abstract_t">Wu M, Huang F, Jiang X, et al. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One 2013; 8:e77805.</a></li><li><a class="nounderline abstract_t">Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica 2011; 96:142.</a></li><li><a class="nounderline abstract_t">Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant 2010; 45:979.</a></li><li><a class="nounderline abstract_t">Hubacek P, Keslova P, Formankova R, et al. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet. Pediatr Transplant 2009; 13:919.</a></li><li><a class="nounderline abstract_t">Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17:591.</a></li><li><a class="nounderline abstract_t">Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17:658.</a></li><li><a class="nounderline abstract_t">Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 2009; 58:253.</a></li><li><a class="nounderline abstract_t">Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70:305.</a></li><li><a class="nounderline abstract_t">Lejniece S, Murovska M, Chapenko S, et al. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient. Exp Oncol 2011; 33:239.</a></li><li><a class="nounderline abstract_t">D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010; 10:E1.</a></li><li><a class="nounderline abstract_t">Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187.</a></li><li><a class="nounderline abstract_t">Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008; 88:443.</a></li><li><a class="nounderline abstract_t">Reddy P, Davenport R, Ratanatharathorn V, et al. West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33:109.</a></li><li><a class="nounderline abstract_t">Brenner W, Storch G, Buller R, et al. West Nile Virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance. Bone Marrow Transplant 2005; 36:369.</a></li><li><a class="nounderline abstract_t">Goebel WS, Conway JH, Faught P, et al. Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient. Pediatr Blood Cancer 2007; 48:222.</a></li><li><a class="nounderline abstract_t">Duband S, Cornillon J, Tavernier E, et al. Toxoplasmosis with hemophagocytic syndrome after bone marrow transplantation: diagnosis at autopsy. Transpl Infect Dis 2008; 10:372.</a></li><li><a class="nounderline abstract_t">Power M, Vandenberghe E, Conneally E, et al. Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia. Bone Marrow Transplant 2005; 36:1019.</a></li><li><a class="nounderline abstract_t">Meers S, Lagrou K, Theunissen K, et al. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis 2010; 50:1127.</a></li><li><a class="nounderline abstract_t">Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008; 14:1089.</a></li><li><a class="nounderline abstract_t">Edvinsson B, Lundquist J, Ljungman P, et al. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS 2008; 116:345.</a></li><li><a class="nounderline abstract_t">Lim Z, Baker B, Zuckerman M, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect 2007; 54:e83.</a></li><li><a class="nounderline abstract_t">Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246:339.</a></li><li><a class="nounderline abstract_t">Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007; 13:1304.</a></li><li><a class="nounderline abstract_t">Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86:3979.</a></li><li><a class="nounderline abstract_t">Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 1994; 14:247.</a></li><li><a class="nounderline abstract_t">Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 2007; 86:69.</a></li><li><a class="nounderline abstract_t">Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28:250.</a></li><li><a class="nounderline abstract_t">Ljungman P, Engelhard D, de la Cámara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35:737.</a></li><li><a class="nounderline abstract_t">Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95:3683.</a></li><li><a class="nounderline abstract_t">Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75:1583.</a></li><li><a class="nounderline abstract_t">Cuthbert RJ, Iqbal A, Gates A, et al. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol 1995; 48:257.</a></li><li><a class="nounderline abstract_t">Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.</a></li><li><a class="nounderline abstract_t">Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40:125.</a></li><li><a class="nounderline abstract_t">Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91:78.</a></li><li><a class="nounderline abstract_t">Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25:151.</a></li><li><a class="nounderline abstract_t">Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407.</a></li><li><a class="nounderline abstract_t">Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19:1111.</a></li><li><a class="nounderline abstract_t">Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83:1971.</a></li><li><a class="nounderline abstract_t">Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.</a></li><li><a class="nounderline abstract_t">Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant 1997; 19:467.</a></li><li><a class="nounderline abstract_t">Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36:509.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Zander A, Vellekoop L, et al. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984; 77:35.</a></li><li><a class="nounderline abstract_t">Hughes WT. Mycobacterial infections in bone marrow transplant recipients. Biol Blood Marrow Transplant 2000; 6:359.</a></li><li><a class="nounderline abstract_t">Gaviria JM, Garcia PJ, Garrido SM, et al. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6:361.</a></li><li><a class="nounderline abstract_t">Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006; 62:421.</a></li><li><a class="nounderline abstract_t">Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428.</a></li><li><a class="nounderline abstract_t">van der Eijk AA, Pas SD, Cornelissen JJ, de Man RA. Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2014; 27:309.</a></li><li><a class="nounderline abstract_t">Peritz DC, Duncan C, Kurek K, et al. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD). J Pediatr Hematol Oncol 2008; 30:931.</a></li><li><a class="nounderline abstract_t">Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr 1996; 128:353.</a></li><li><a class="nounderline abstract_t">Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152:1172.</a></li><li class="breakAll">Fetscher S, Technau K, Lange W. Herpes zoster after high dose chemotherapy and autologous stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplanation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.</li><li class="breakAll">Wessels M, Nevill T, Le A, et al. Incidence and factors predictive of varicella-zoster virus infection following stem cell transplantation. In: 25th annual meeting European Group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.</li><li><a class="nounderline abstract_t">Atkinson K, Meyers JD, Storb R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29:47.</a></li><li><a class="nounderline abstract_t">Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia. Haematologica 2005; 90:EIM04.</a></li><li><a class="nounderline abstract_t">Patel SR, Ortín M. Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant. J Pediatr Hematol Oncol 2005; 27:106.</a></li><li><a class="nounderline abstract_t">Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13:277.</a></li><li><a class="nounderline abstract_t">Webster A, Grint P, Brenner MK, et al. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989; 27:117.</a></li><li><a class="nounderline abstract_t">Safdar A, Papadopoulous EB, Armstrong D. Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Bone Marrow Transplant 2002; 29:913.</a></li><li><a class="nounderline abstract_t">Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10:300.</a></li><li><a class="nounderline abstract_t">Suzuki J, Ashizawa M, Okuda S, et al. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2012; 14:E7.</a></li><li><a class="nounderline abstract_t">Fukuno K, Tomonari A, Takahashi S, et al. Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia. Int J Hematol 2006; 84:79.</a></li><li><a class="nounderline abstract_t">Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007; 7:460.</a></li><li><a class="nounderline abstract_t">Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32:97.</a></li><li><a class="nounderline abstract_t">Bokhari S, Das-Gupta E, Russell N, Byrne J. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. Bone Marrow Transplant 2008; 42:281.</a></li><li><a class="nounderline abstract_t">Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004; 28:794.</a></li><li><a class="nounderline abstract_t">Islam MS, Anoop P, Gordon-Smith EC, et al. Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders. Hematology 2010; 15:344.</a></li><li><a class="nounderline abstract_t">Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011; 117:5835.</a></li></ol></div><div id="topicVersionRevision">Topic 1403 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466269" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19769539" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758577" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections in patients with chronic lymphocytic leukemia treated with fludarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552214" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946062" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476432" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807886" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242599" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Y238X stop codon polymorphism in the humanβ-glucan receptor dectin-1 and susceptibility to invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803380" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Immune correlates of protection in human invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203722" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944139" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20596732" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943529" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807708" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873123" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9885208" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469254" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of fever in patients with cancer and treatment-induced neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769290" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542320" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8211220" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infections in allogeneic bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2996686" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antiviral therapy in the immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11081387" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16435018" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412059" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427356" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22692506" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861981" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Viral disease prevention after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738616" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984943" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115967" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042657" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918077" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218877" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12689933" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242529" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562695" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151423" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764172" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585797" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26726945" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983552" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707997" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494906" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563077" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468152" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715308" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322189" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention and treatment of CMV infection after allogeneic bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2833959" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205091" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7561213" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815488" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16845427" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23994819" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249208" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18781540" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20973823" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430084" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837781" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : How I treat adenovirus in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640184" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176880" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11247710" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Adenovirus infections in adult recipients of blood and marrow transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666361" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23092814" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184180" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146063" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7038501" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Infectious gastroenteritis in bone-marrow-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19705974" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21487110" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113671" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9208124" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167618" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18428141" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382252" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380010" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551005" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621466" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144658" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433917" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Allogeneic hematopoietic cell transplant in HCV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373370" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347135" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578413" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578413" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176615" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498717" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410183" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19708893" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888253" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : BKV infection and hemorrhagic cystitis after allogeneic bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982496" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845896" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385622" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128571" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : BK virus-associated bilateral ureteric stenosis after haematopoietic SCT: viral kinetics and successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396475" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660716" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122137" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920307" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824982" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606551" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impact of human herpesvirus-6 after haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124621" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851868" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190836" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067913" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20732435" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616809" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Progressive multifocal leukoencephalopathy in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141745" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21823157" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Progressive multifocal leukoencephalopathy in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217715" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223720" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350666" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Rituximab-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18855101" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566328" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15968282" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : West Nile Virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333839" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18384483" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Toxoplasmosis with hemophagocytic syndrome after bone marrow transplantation: diagnosis at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205728" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218875" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018809" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prevention of toxoplasmosis in transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452424" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16806484" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10399863" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cyclosporine neurotoxicity: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950917" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579369" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994240" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435587" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1887253" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Chronic graft-versus-host disease and other late complications of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750612" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845897" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317564" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7730489" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Functional hyposplenism following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14986163" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530009" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434374" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236396" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cytomegalovirus in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393659" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193754" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142663" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443467" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9052913" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6356515" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Mycobacterial infections in marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6430082" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Mycobacterial pulmonary infections after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917570" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Mycobacterial infections in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917571" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413085" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Tuberculosis in stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156482" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24977683" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Hepatitis E virus infection in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131784" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774503" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Herpes zoster infection after bone marrow transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905982" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Infection with varicella-zoster virus after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905982" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Infection with varicella-zoster virus after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905982" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Infection with varicella-zoster virus after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6245486" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16464763" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701988" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8199570" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2537881" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12080357" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765103" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Central nervous system infection with Listeria monocytogenes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22340704" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16867908" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597570" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Viral dynamics in transplant patients: implications for disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815484" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490912" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166672" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20863430" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454450" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
